See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>
- AMNOG-Monitor Analysis · Pricing · Prediction (325 KB)
Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement.
Dear readers of the AMNOG monitor,
In June 2021, there were a further 11 G-BA resolutuions on early benefit assessments, the results of which are summarised in the following table. A total of 691 procedures have now been completed, and in 2021 alone, 135 new G-BA resolutions on early benefit assessments are expected. This is an increase of 40% compared to the old records of 2020 and 2019, respectively.
Resolutions June 2021
Changes in rimbursement prices were observed in June 2021 for the following AMNOG products: Binimetinib (Mektovi®), Brigatinib (Alunbrig®),Damoctocog alfa pegol (Jivi®), Darolutamid (Nubeqa®), Encorafenib (Braftovi®), Givosiran (Givlaari®), Ivacaftor (Kalydeco®), Lorlatinib (Lorviqua®), Pegvaliase (Palynziq®), Mogamulizumab (Poteligeo®) and Venetoclax (Venclyxto®).
Digitial health care is the topic of a new expert report of the German Council of Health Experts (Sachverständigenrat Gesundheit). Against the background of the current pandemic with digital vaccination passports and containment management, this is of particular urgency. The experts conclude that Germany is far behind other countries. They plead for a targeted strategy for digital health, with a legal framework set by the public authorities, the generation of scientific evidence and quality assurance, as well as access to the findings to all stakeholders, both in terms of medical care for the individual and a targeted development of the health care system as a whole. https://www.svr-gesundheit.de/fileadmin/Gutachten/Gutachten_2021/SVR_Gutachten_2021.pdf
Speaking of digitisation: In July 2021, we will present the 100th edition of the AMNOG monitor! Instead of grand speeches, we are again implementing a number of important innovations that will help our customers in their daily work, such as a simplified and improved export of own analyses to Excel and the option to save configurations (bookmarks) for Interactive analyses, which can then be updated at the push of a button, for example whenever new G-BA resolutions become available.
We look forward to further cooperation with you.
Dr Johannes Hankowitz, Christian Rieke